Sir,
Aminoglycosides are widely used to treat MDR Gram-negative bacterial infections with bactericidal activity mediated by binding the 16S rRNA aminoacyl-tRNA recognition site to prevent protein synthesis. Multiple aminoglycoside resistance mechanisms have been documented including 16S rRNA modification. 1 NpmA, an uncommon 16S rRNA methyltransferase originally identified in a clinical Escherichia coli isolate confers pan-aminoglycoside resistance. 2 In this study, routine WGS of hospital-acquired Clostridioides (Clostridium) difficile identified npmA in the genome of a clinical isolate (CD7814). C. difficile is a Gram-positive, spore-forming enteric pathogen and the cause of most hospital-acquired, antibiotic-associated diarrhoea. The epidemiology of C. difficile has changed in the past several decades with infections increasingly being reported outside of acute care settings. 3 The discovery of npmA in the genome of a clinical C. difficile isolate has implications for the spread of aminoglycoside resistance.
Clinical C. difficile isolates are routinely sequenced using Illumina NextSeq500 and Nextera libraries as part of an infection prevention initiative at our hospital. 4 Genomes are assembled using SPAdes, annotated with Prokka and characterized by searches of ResFinder and pubMLST databases (https://pubmlst.org/cdifficile/). [5] [6] [7] This analysis identified NpmA-coding sequences in C. difficile isolate CD7814 belonging to ST11. CD7814 carries two additional aminoglycoside resistance determinants: (i) aph(3 0 )-III, which encodes an aminoglycoside phosphotransferase; and (ii) ant(6)-Ia, which encodes an aminoglycoside nucleotidyltransferase. Aminoglycoside susceptibility testing was performed by Etest on CD7814 and two additional ST11 isolates from our hospital that lack npmA (CD7861 and CD7786). Cell suspensions corresponding to 0.5 McFarland were prepared and plated onto Brucella blood agar plates supplemented with vitamin K 1 and haemin (Anaerobe Systems, Morgan Hill, CA, USA). Etest strips (bioMérieux, Durham, NC, USA) were applied and the plates were incubated anaerobically at 37
C for 48 h as previously described. 8 Etests were read according to the manufacturer's instructions. CD7814 demonstrated high-level resistance to gentamicin (.256 mg/L) relative to CD7861 (64 mg/L) and CD7786 (24 mg/L). High-level resistance to tobramycin and amikacin was observed in all ST11 C. difficile isolates tested. Although CLSI breakpoints for C. difficile are not defined for aminoglycosides, these data suggest that NpmA is expressed and associated with increased gentamicin resistance in CD7814.
Genomic analysis of the CD7814 assembly identified a large, presumably chromosomal contig of 150 kb containing the npmA gene. The majority of predicted ORFs surrounding npmA in CD7814 are hypothetical proteins whereas others encode proteins involved in recombination suggesting that npmA was acquired via horizontal gene transfer, which is consistent with the mosaic structure of the C. difficile chromosome (Figure 1a) . 9 Five additional C. difficile genomes bearing npmA gene sequences that show 99% nucleotide identity to npmA from CD7814 and pARS3 were identified through BLAST and PubMed literature searches ( Figure 1a ). The DNA sequence flanking npmA in CD7814 shows little or no nucleotide identity to either E. coli pARS3 or the five C. difficile npmA flanking regions. The five C. difficile genomes are of human and animal origin and were collected from three different continents over a period of at least 10 years. Interestingly, these C. difficile isolates belong to three different STs but their genomes share 99% nucleotide identity across 3kb of the npmA region ( Figure 1a) . None of the five C. difficile genomes share any other sequence similarity to pARS3 outside of npmA. Together, these genomic data suggest that npmA is carried on a conserved element in the five C. difficile genomes and that the mechanism of npmA acquisition in CD7814 is different. In addition, all five C. difficile genomes encode a missense mutation in npmA resulting in a K131N substitution in NpmA relative to CD7814 and pARS3 sequences (Figure 1b) . To maintain the established nomenclature for 16S rRNA methyltransferase genes, the CD7814 and, by default, the E. coli pARS3 npmA genes can be re-designated as npmA1 while npmA sequences containing the K131N mutation can be designated npmA2.
10 CD7814 npmA1 has been deposited in GenBank under accession number MH249957.
To the best of our knowledge, this is the first description of npmA and high-level aminoglycoside resistance in a hospitalacquired C. difficile isolate. Because of strict anaerobic growth conditions, Etest is the most practical method to measure antibiotic susceptibility in C. difficile. As Etests for aramycin and neomycin are unavailable, a limitation of this study is our inability to demonstrate the specificity of NpmA methyltransferase activity for the N1-A1408 16S rRNA. However, the nucleotide identity between CD7814 npmA and the original E. coli sequence and the high-level aminoglycoside resistance observed support NpmAmediated resistance in this clinical C. difficile isolate. To the best of our knowledge, no evidence to support high-level gentamicin resistance in the presence of ant(6)-Ia and aph(3 0 )-III has been reported.
In conclusion, this study demonstrates the presence of npmA and high-level aminoglycoside resistance in a clinical C. difficile isolate. The ability of C. difficile to persist in the environment as a spore former may facilitate acquisition of novel antibiotic resistance determinants. These data suggest that hospital-acquired C. difficile may be a reservoir for uncommon antibiotic resistance determinants such as npmA.
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None to declare. Sir, The importance of colistin in treating life-threatening infections caused by MDR bacteria is increasing. In this regard, dissemination of bacteria harbouring the mobile colistin resistance gene (mcr) in food animals has been highlighted, owing to the abundant usage of colistin in the agricultural sector in developing countries. 1 Although the prevalence of colistin-resistant bacteria in healthy human residents in these countries is unclear, a high prevalence of MDR bacteria in the faecal microbiota of residents in Vietnam and surrounding nations was recently revealed.
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2 Therefore, here we examined the occurrence of dissemination of colistin-resistant bacteria harbouring mcr in the faecal microbiota of healthy residents of a representative Vietnamese village. Table 1 .
One stool specimen was obtained from each participant using a transport swab with Cary-Blair transport medium (Eiken Chemical, Tokyo, Japan). Specimens were inoculated on selective agar medium (CHROMagar TM COL-APSE, CHROMagar, Paris, France) for isolation of colistin-resistant Gram-negative bacteria. The resulting Enterobacteriaceae-like colonies were isolated and characterized further for bacterial identification, antibiotic susceptibility, resistance genes and relevance between isolates, as described previously. [3] [4] [5] The study was approved by the Ethics Committees of Osaka University (yakujin 29-8) and Thai Binh University of Medicine and Pharmacy (no. 773.1). All participants provided written informed consent. For any participant younger than 18 years, written informed consent was obtained from the respective parents.
As shown in Table 1 , most of the stool specimens were culture positive on a selective-medium plate (CHROMagar TM COL-APSE). Among these colonies, colistin-resistant Escherichia coli (CR-E) that exhibited MICs of colistin between 8 and 16 mg/L were detected in 69 out of 98 specimens tested. The proportion of households that had members carrying CR-E was also quite high at 80.6% (29 positive, out of 36 households tested). Furthermore, almost all colistinresistant isolates possessed mcr-1 and/or mcr-3, except one that did not contain mcr-1 to -5, as determined by PCR.
PFGE analysis of CR-E isolates showed that, within a household, the members of five households carried a similar strain, but between households there were no similar strains ( Figure S1 , available as Supplementary data at JAC Online).
Resistance profiles of CR-E to other antibiotics varied between 0 and 11, out of the 14 antibiotics tested (ampicillin, cefoxitin, cefotaxime, ceftazidime, meropenem, streptomycin, kanamycin, gentamicin, ciprofloxacin, nalidixic acid, tetracycline, chloramphenicol, fosfomycin and trimethoprim/sulfamethoxazole). The average number of antibiotics to which isolates were resistant was 5.6. The rate of MDR, defined as resistance to at least one antibiotic drug in three or more antibiotic classes, 6 of CR-E isolates was determined to be 92.8% (64/69). There were no carbapenem-or fosfomycinresistant CR-E isolates (Table S1 ).
In contrast to the studies conducted on colistin-resistant bacteria in food animals, there have been only limited studies on the prevalence of colistin-resistant bacteria with mcr in healthy individuals. However, one recent study focused on mcr-1-carrying bacteria in the faecal samples of chicken farmers in Vietnam. 7 This study reported that 25% of farmers were colonized with mcr-1-carrying bacteria that grew on non-selective medium. However, this protocol may have the potential to lose CR-E strains owing to the abundant susceptible bacteria in stool specimens. As a result, it is difficult to obtain the true prevalence of colistin-resistant bacteria in stool specimens. In the current study, we utilized the selective medium, CHROMagar TM COL-APSE, for identifying colistin- 
